Page 28 - 2019_08-Haematologica-web

C. Baer et al.
hematopoiesis with oncogenic potential
(CHOP): separation from CHIP and roads to
AML. Int J Mol Sci. 2019;20(3).
40. Wrzeszczynski KO, Felice V, Abhyankar A,
et al. Analytical validation of clinical whole- genome and transcriptome sequencing of patient-derived tumors for reporting tar- getable variants in cancer. J Mol Diagn. 2018;20(6):822-835.
41. Kennedy AL, Shimamura A. Genetic predis- position to MDS: clinical features and clonal evolution. Blood. 2019;133(10):1071-1085.
42. da Silva-Coelho P, Kroeze LI, Yoshida K, et al. Clonal evolution in myelodysplastic syn- dromes. Nat Commun. 2017;8:15099.
43. Klintman J, Barmpouti K, Knight SJL, et al.
Clinical-grade validation of whole genome sequencing reveals robust detection of low- frequency variants and copy number alter- ations in CLL. Br J Haematol. 2018;182(3): 412-417.
genes/pathways and clinical associations.
Blood. 2018;132(12):1225-1240.
47. Loh PR, Genovese G, Handsaker RE, et al.
Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature. 2018;559(7714):350-355.
48. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-
44. Höllein A, Twardziok SO, Walter W, et al.
WGS and RNA-seq is superior to conven-
tional diagnostic tests in multiple myeloma:
ready for prime time? Blood. 2018;132 350.
(Suppl. 1):4442.
45. Khurana E, Fu Y, Chakravarty D, et al. Role
of non-coding sequence variants in cancer.
Nat Rev Genet. 2016;17(2):93-108.
46. Pellagatti A, Armstrong RN, Steeples V, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated
49. Sundaram L, Gao H, Padigepati SR, et al. Predicting the clinical impact of human mutation with deep neural networks. Nat Genet. 2018;50(8):1161-1170.
50. Zomnir MG, Lipkin L, Pacula M, et al. Artificial intelligence approach for variant reporting. JCO Clin Cancer Inform. 2018;2.
1520
haematologica | 2019; 104(8)